Effectiveness of Dupilumab for management of moderate and severe atopic dermatitis

Summaries 3 min 321

Font Size

Created On: 09/05/2023

This post hoc analysis was carried out to check the response of monoclonal antibody Dupilumab by baseline atopic dermatitis severity in adolescent and adult patients with moderate-to-severe atopic dermatitis.

See All

Key take away

In people with moderate or severe atopic dermatitis, Dupilumab with or without topical corticosteroids have comparable effectiveness.

Background

Method

From 5 double-blind, randomized, placebo-controlled studies, 1719 volunteers (aged 12 years or more) with atopic dermatitis had their Dupilumab response measured via the severity of their atopic dermatitis at baseline. Patients were given topical corticosteroids (TCS) (adults; 16/52 weeks), or subcutaneous placebo or Dupilumab as monotherapy (300 mg [adults, adolescents] or 200 mg [adolescents] every two weeks; 16 weeks). According to the baseline Investigator's Global Assessment (IGA) score (3 [moderate]/4 [severe]), participants were categorized.

Result

In comparison to individuals with severe atopic dermatitis, a numerically greater absolute proportion of patients with moderate atopic dermatitis who received Dupilumab attained IGA 0/1 (clear/almost clear). The risk differences between Dupilumab and placebo were 16.4–34.2 for severe atopic dermatitis and 18.9–35.5 for moderate atopic dermatitis. There were no discernible distinctions or consistent response patterns between the moderate and severe categories for all the other outcomes studied.

Conclusion

The baseline severity of atopic dermatitis does not influence the effectiveness of Dupilumab treatment.

When compared to placebo with or without TCS, Dupilumab with or without TCS consistently showed remarkable effectiveness in quality of life, patient-reported itch, and clinical symptoms both in patients with severe and moderate atopic dermatitis.